San Diego Biotech in 2030: A Center for Stem Cells, Genomics, Software, Neuroscience

The image of the double helix has captivated the public imagination for a long time. But biotechnology today actually requires what you might call a triple helix of money, people, and ideas, according to John Mendlein, the chairman of San Diego-based Fate Therapeutics. All three ingredients were in one place Wednesday night for Xconomy’s event … Continue reading San Diego Biotech in 2030: A Center for Stem Cells, Genomics, Software, Neuroscience